Injectable HIV prevention drug could help Northern Ireland reach 2030 goal

LGBTQ+ advocates and health campaigners are urging the Department of Health (DoH) in Northern Ireland to embrace cabotegravir (CAB-LA), a long-acting injectable drug for HIV prevention. Following announcements of its introduction in England and Wales, mirroring Scotland's policy, the call for its adoption in Northern Ireland aims to align with the shared ambition of ending new UK HIV cases by 2030.

Cabotegravir, administered as an injection six times annually, presents a discreet and convenient alternative to daily oral PrEP (pre-exposure prophylaxis) pills. As the BBC reports, This development is particularly significant for individuals who may face challenges with consistent daily medication due to factors such as accessibility, personal circumstances, or concerns about privacy.

Scott Cuthbertson, CEO of the Rainbow Project, emphasized the potential of cabotegravir as a "game-changer" in HIV prevention. "Northern Ireland has committed to the target of ending HIV transmission by 2030, but to reach that target we need to be bold and innovative," Cuthbertson stated. "For those who can't take or struggle with current HIV prevention methods, it adds a further option in the growing arsenal of preventative medication."

Lea Dickson of Positive Life, Northern Ireland's dedicated HIV charity, expressed concern that Northern Ireland could be left behind, stating it would "be deeply disappointing if Northern Ireland did not get access to this new drug." Dickson further highlighted the need for a more proactive approach to HIV prevention in the region. "We're close to eliminating new HIV diagnoses here, but we can't achieve that without a focused and adequately funded effort," she asserted. "Any healthcare innovation which empowers people to proactively look after their sexual health must be supported and actively promoted."

The DoH acknowledged the guidance issued by the National Institute for Health and Care Excellence (NICE) recommending cabotegravir for HIV prevention. In a statement released Friday, the DoH indicated that the department will consider the final guidance, expected on November 5th, 2025, to ensure alignment with treatments recommended for routine use in the NHS in England.

The introduction of cabotegravir represents a significant stride forward in HIV prevention, offering a more accessible and discreet option for individuals seeking to protect their health. Advocates hope its implementation in Northern Ireland will contribute to achieving the collective goal of ending new HIV transmissions by 2030, fostering a healthier and more inclusive future for all.